Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma (NCT07259317)
A Phase 2, Single-Arm Trial of Relacorilant in Combination With Nab-Paclitaxel and Gemcitabine in Chemotherapy-Naïve Patients With Metastatic Pancreatic Adenocarcinoma (TRIDENT)
🩺 Plain-English Summary (8th-Grade Level)
This is a 2-part, Phase 2 study to evaluate the safety, tolerability, dosing, pharmacokinetics (PK), and efficacy of relacorilant in combination with nab-paclitaxel and gemcitabine in chemotherapy-naïve patients with metastatic pancreatic adenocarcinoma (PDAC).
Who can join: Review the eligibility criteria below.
Location: Site 02 — Scottsdale, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (16 Sites)
- Site 02 — Scottsdale, Arizona
- Site 04 — Los Angeles, California
- Site 12 — Orange, California
- Site 06 — Atlanta, Georgia
- Site 14 — Goshen, Indiana
- Site 15 — Westwood, Kansas
- Site 03 — Grand Rapids, Michigan
- Site 10 — East Brunswick, New Jersey
- Site 11 — Morristown, New Jersey
- Site 08 — Albany, New York
- Site 05 — Lake Success, New York
- Site 07 — Shirley, New York
- Site 13 — Cincinnati, Ohio
- Site 09 — Nashville, Tennessee
- Site 16 — Fort Worth, Texas
- Site 01 — San Antonio, Texas
📞 Contact the Study Coordinator
Phone: (650) 815-1595
Email: corceptstudy558@corcept.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Adenocarcinoma
- Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance — Bethesda, Maryland
- Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors — Orange, California
Explore by condition: All Adenocarcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.